- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04347304
Effects of Flavanol-rich Dark Chocolate Consumption on Metabolic Profiles Among Obese Adults Using Metabolomics Approach
Effects of Flavanol-rich Dark Chocolate Consumption on Metabolic Profiles Among Obese
Obesity has become a global issue due to its alarming high and increasing prevalence worldwide and the roles it plays in occurrence of many chronic diseases. In addition, obesity is characterized as a state of chronic, low-grade inflammation and is associated with an abnormal inflammatory response, low antioxidant capacity and reduced insulin sensitivity which lead to the generation of inflammation, oxidative stress and insulin resistance.
As in Malaysia, study by National Health and Morbidity Survey Malaysia (NHMS) in 2011 and 2015 showed a continuing increase of the problem. In response to the rise of obesity prevalence, various efforts and strategies have been implemented in the past decade to combat this problem. The use of natural products as therapeutic agents in preventing metabolic disease has becoming popular. Cocoa and its products is a largely consumed food in the world. It has a very rich sources of phenolic compound. Several in vitro and in vivo studies have shown that polyphenols, with antioxidant, anti-inflammatory and anti-obesity properties, can boost energy expenditure and thermogenesis, lessen oxidative stress and inflammation while supporting weight loss management. Furthermore, the contribution of human studies especially among obese relatively limited.
The popularity of chocolate and/or cocoa and its frequent consumption made it the target of many research studies, due to its favourable effects, and to the significant role it may exert on improving the obesity condition. Therefore, this study aims to investigate the effects of flavanol-rich dark chocolate consumption on metabolic profiles of obese adults using metabolomic approach.
Study Overview
Status
Conditions
Detailed Description
Overnutrition and sedentary lifestyle are the leading factors associated with the development of obesity. Obese adults usually are advised to make lifestyle modifications which include dietary restriction and physical activity recommendation. In addition, dietary supplements and medication such as anti-hypertensive, lipid lowering drugs are used to achieved targeted body weight of obese adult. Therefore, the confounding factors in this study namely dietary intake, physical activity, medication, supplements were controlled throughout the study. These factors including smoking were also controlled as it will affect the metabolites.
Imbalance between energy intake and expenditure results in adipose tissue expansion due to excessive lipogenesis in adipose tissues. Generally, it is well accepted that adipose tissue expansion in an obese state is accompanied by elevated inflammation. Oxidative stress and pro-inflammatory processes are strongly related. Increased abdominal adipose tissue accelerates the production of pro-inflammatory cytokines which promote increased generation of ROS, both inflammation and oxidative stress play a significant role in the development of insulin resistant thus further are associated with the degree of metabolic dysfunction.
It was hypothesized that cocoa flavanol with the properties of anti-inflammation, anti-oxidative and antiobesity properties may reduce the oxidative stress and inflammation, subsequently reduce the insulin resistance and thus improved the outcome measurements in obese adult. In order to measures the altered metabolite in the urine and blood serum following cocoa rich flavanol consumption in dark chocolate in obese adult, a metabolomics based approach is used in this study.
This study is a randomized, open-labelled, parallel controlled trial where the intervention group will receive 20 grams of dark chocolate, daily for 12 weeks while the control group will receive 20 grams of white chocolate daily for 12 weeks. Measurement will be taken including sociodemographic, anthropometric measurement, diet and physical activity questionnaire, blood and urine samples at baseline and 12 weeks of intervention. Obese male adult aged 18-45 years old will be recruited
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zulfitri Azuan Mat Daud, PhD
- Phone Number: +60397692431
- Email: zulfitri@upm.edu.my
Study Locations
-
-
Selangor
-
Seri Kembangan, Selangor, Malaysia, 43400
- Recruiting
- Universiti Putra Malaysia
-
Contact:
- Zulfitri Azuan Mat Daud, PhD
- Phone Number: 60397692431
- Email: zulfitri@upm.edu.my
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Malaysian
- Obese BMI ≥ 25.0 kg/m2
- Not on any drug or herbal preparation, antioxidative or any drugs or dietary supplement.
- Do not have any chronic diseases
- Do not have allergy to cocoa
- Age 18-45 years old.
Exclusion Criteria:
- Non-Malaysian
- BMI < 25.0 kg/m2
- Smokers and alcohol drinkers
- Participants with cardiovascular diseases, hypertension or diabetes
- Participants taking medications that affect insulin, glucose, lipid or blood pressure levels
- Participants taking any dietary supplements
- Have allergy towards cocoa beverages
- Participants who are currently involved in a weight management program
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: cocoa polyphenols
21 grams of dark chocolate (289 mg polyphenols)
|
subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
|
|
Placebo Comparator: polyphenols free
21 grams of white chocolate (0 mg polyphenols)
|
subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in insulin resistance at 12 week
Time Frame: baseline and 8 weeks
|
Insulin resistance will be determined HOMA-IR and calculated as HOMA-IR = fasting serum x fasting blood glucose/22.5.
|
baseline and 8 weeks
|
|
change in insulin sensitivity at 8 weeks
Time Frame: baseline and 8 weeks
|
To assess insulin sensitivity, Quantitative Insulin Sensitivity Check Index (QUICKI) will be used and cutt off point of less than 0.33 indicates reduced insulin sensitivity
|
baseline and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in body weight at 8 weeks
Time Frame: baseline and 8 weeks
|
Body weight will be measured in kilograms using SECA electronic scale model 703.
|
baseline and 8 weeks
|
|
change in waist circumference at 8 weeks
Time Frame: baseline and 8 weeks
|
Waist circumference will be assessed at the midpoint between the lowest rib andd the iliac crest using a non-stretchable tape measure.
The measurement will be conducted twice to the nearest 0.1cm.
The cutoff points for waist ciircumference by WHO expert committee on obesity in Asian and Pacific populations are >90 cm for men and >80cm fro women.
|
baseline and 8 weeks
|
|
change in lipid profiles (TG, HDL-c, LDL-c, TC) at 8 weeks
Time Frame: baseline and 8 weeks
|
Lipid profiles (TG, Cholesterol, LDL-c, and HDL-c) will be determined using commercially available kits using Architect ci8200 analyzer
|
baseline and 8 weeks
|
|
change in inflammatory markers (C-reactive protein ) at 8 week
Time Frame: baseline and 8 weeks
|
C-reactive protein will be measured using kits of human inflammatory cytokines by Enzyme Linked Inmuno Sorbent Assay from blood serum and will be expressed as mg/L.
|
baseline and 8 weeks
|
|
change in oxidative stress markers (oxidized LDL) at 8 week
Time Frame: baseline and 8 weeks
|
Levels of LDL-ox in plasma will be analysed at the beginning and the end (8 weeks) and will be expressed as mg/L.
|
baseline and 8 weeks
|
|
changes in metabolomics profiles following flavanol-rich dark chocolate consumption at 8 week
Time Frame: baseline and 8 weeks
|
Metabolomic analysis of the plasma sample will be performed using 1H-NMR platform
|
baseline and 8 weeks
|
|
changes in gut microbiome status following flavanol-rich dark chocolate consumption at 8 week
Time Frame: baseline and 8 weeks
|
metagenomic analysis of fecal samples will be analysed at the beginning and end (8 weeks)
|
baseline and 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Amin Ismail, PhD, Universiti Putra Malaysia
Publications and helpful links
General Publications
- Moazzami AA, Bondia-Pons I, Hanhineva K, Juntunen K, Antl N, Poutanen K, Mykkanen H. Metabolomics reveals the metabolic shifts following an intervention with rye bread in postmenopausal women--a randomized control trial. Nutr J. 2012 Oct 22;11:88. doi: 10.1186/1475-2891-11-88.
- Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med. 2000 May 15;28(10):1456-62. doi: 10.1016/s0891-5849(00)00252-5.
- Suhre K, Meisinger C, Doring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM, Mewes HW, Hrabe de Angelis M, Wichmann HE, Kronenberg F, Adamski J, Illig T. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One. 2010 Nov 11;5(11):e13953. doi: 10.1371/journal.pone.0013953.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NMRR-19-3092-51617.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Dark chocolate (20 grams) per day providing 508 mg of polyphenols
-
Queen's University, BelfastBelfast Health and Social Care TrustCompletedHypertensionUnited Kingdom
-
Ayesha De CostaBoston Children's Hospital; Muhimbili University of Health and Allied Sciences and other collaboratorsCompleted
-
University of Illinois at ChicagoCompleted
-
Hospices Civils de LyonCompletedChronic Spontaneous Urticaria
-
International Centre for Diarrhoeal Disease Research...Karolinska InstitutetCompletedTesting Effect of Intervention
-
Forest LaboratoriesCompletedGeneralized Anxiety DisorderUnited States